Search

Displaying results 4491 - 4500 of 9333 in total
  1. Drug

    Muraglitazar

    go.drugbank.com/drugs/DB06510
    Investigational

    It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes. … Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes.

  2. Drug

    Human papillomavirus type 31 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10310
    ApprovedInvestigational

    The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 31 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 31.

  3. Drug

    Indium In-111 imciromab pentetate

    go.drugbank.com/drugs/DB09339
    ApprovedWithdrawn

    Indium In-111 imciromab pentetate is a mouse monoclonal antibody labelled with the radioisotope Indium-111 which was used for cardiac imaging under the trade name Myoscint, but was withdrawn in 1993.

  4. Drug

    GSK-923295

    go.drugbank.com/drugs/DB06097
    Investigational

    GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline … GSK-923295 is the first drug candidate to enter human clinical trials that specifically targets CENP-E and is currently in Phase I human clinical trials being conducted by GSK.

  5. Drug

    Sunvozertinib

    go.drugbank.com/drugs/DB18925
    Investigational

    [A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor … [A40018] EGFR often have mutations that lead to unfavourable treatment options and prognosis.

  6. Drug

    Inosinic Acid

    go.drugbank.com/drugs/DB04566
    Investigational

    A purine nucleotide which has hypoxanthine as the base and one phosphate group esterified to the sugar moiety.

  7. Drug

    PEV3A

    go.drugbank.com/drugs/DB05144
    Investigational

    The elicited antibodies are highly specific and able to inhibit the parasite’s ability to invade liver tissue _in vitro_. … The two synthetic peptide vaccine components mimic the native structure of important antigens of the malaria parasite.

  8. Drug

    Meclocycline

    go.drugbank.com/drugs/DB13092
    Investigational

    Meclocycline is under investigation in clinical trial NCT00385515 (Efficacy of SNX-1012 in the Treatment of Oral Mucositis) [L797].

  9. Drug

    Thrombomodulin Alfa

    go.drugbank.com/drugs/DB05777
    Approved

    It is a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disseminated intravascular

  10. Drug

    CR002

    go.drugbank.com/drugs/DB05139
    Investigational

    This is a novel therapeutic approach to treat kidney inflammation. … CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation.